Moderna is pitching its coronavirus vaccine at about $50 to $60 per course, according to people familiar with talks between the company and potential buyers — higher than other vaccine makers have agreed to charge governments.
The price would apply to the US and other high-income countries, which the company intended to prioritise, said other people familiar with its plans.
The Boston-based biotech’s shares have soared almost 325 per cent this year as its vaccine showed early signs of effectiveness and it became the first in the US to enter clinical trials. This week it expanded its funding deal with the US government, which has now put close to $1bn into the vaccine’s development.
您已閱讀17%（688字），剩餘83%（3339字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。